Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/F/TAF vs ABC/DTG/3TC in Treatment-Naive HIV-1
NCT02607930Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of bictegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Nov 2015; status: completed.
02
Drugs
bictegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02607930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607930.